Who makes J65 vaccine then E39 vaccine?

J65 vaccine then E39 vaccine is developed by COL George Peoples, MD, FACS.

What development phase is J65 vaccine then E39 vaccine in?

J65 vaccine then E39 vaccine is in Phase 1.

Last reviewed 2026-04-19 · How we verify

J65 vaccine then E39 vaccine

COL George Peoples, MD, FACS · Phase 1 active Biologic

At a glance

Generic name	J65 vaccine then E39 vaccine
Also known as	J65 peptide (EIWTFSTKV, Folate Binding Protein), GM-CSF (Sargramostim), E39 peptide (EIWTHSYKV, Folate Binding Protein, 191-199)
Sponsor	COL George Peoples, MD, FACS
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

J65 vaccine then E39 vaccine CI brief — competitive landscape report
J65 vaccine then E39 vaccine updates RSS · CI watch RSS
COL George Peoples, MD, FACS portfolio CI